Lung Cancer Considered

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by Current sponsors: • AbbVie • AstraZeneca • Gilead • J&J • Summit

Denne podkasten er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(392)

FDA Approval: Sunvozertinib for EGFR Exon 20

FDA Approval: Sunvozertinib for EGFR Exon 20 by IASLC

15 Jul 202541min

LCC in Portuguese: Virtual Tumor Board - EGFR NSCLC

LCC in Portuguese: Virtual Tumor Board - EGFR NSCLC by IASLC

11 Jul 202546min

IASLC_WCLC 2025 Preview

IASLC_WCLC 2025 Preview by IASLC

8 Jul 202545min

Virtual Tumor Board: Resectable EGFR NSCLC

In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Chunxia Su and Dr. Collin Blakely. The case explores resectable EGFR NSCLC.

1 Jul 202539min

FDA Approval: Taletrectinib and ROS1 NSCLC

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for NSCLC with a ROS1 gene fusion. Dr. Enri...

24 Jun 202529min

IASLC - ASCO 2025 Highlights

ASCO 2025 Highlights Guests: Charu Aggarwal, MD, MPH Leslye M. Heisler Professor of Medicine Section Chief, Thoracic and Head & Neck Cancer Associate Director, Penn Center for Cancer Care Innovation...

6 Jun 202555min

FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC

In this episode, we will discuss the FDA approval of telisotuzumab vedotin, an antibody drug conjugate, for NSCLC with high c-MET expression. To help review the data and offer perspective on this new ...

27 Mai 202533min